Plain-English translation of NCT06841042 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a medication called SCTB35 to see if it can safely and effectively treat systemic lupus erythematosus (SLE), a serious condition where your immune system attacks your own body. The study will first determine the right dose of the medication, then test how well it works in a larger group of patients. Researchers want to understand how the medication moves through your body and whether it reduces lupus symptoms and flare-ups.
Systemic lupus erythematosus is a complex disease that can be hard to control with existing treatments, and many patients continue to have symptoms despite standard therapy. This trial exists to see if this new medication could offer another treatment option that might help more people with lupus live better, with fewer disease flare-ups and symptoms.
You likely qualify if…
You likely don't qualify if…
You will receive injections of the medication SCTB35 every 21 days (once per cycle). The study has two parts: first, researchers will gradually increase doses in some participants to find the safest and most effective dose; then, more participants will receive the recommended dose to further test how well the treatment works. You'll have regular visits for blood tests, physical exams, and check-ins on how you're feeling, and you'll need to use reliable contraception throughout the study and for 6 months after your last dose.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
China